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NEURAL REGENERATION RESEARCH 
PERSPECTIVE
Rifampicin quinone pretreatment 
improves neuronal survival by 
modulating microglia inflammation 
induced by α-synuclein 
The World Health Organization has predicted that neurodegenerative diseases 
affecting the motor function will become the second most prevalent cause of 
death in the next 20 years. New therapies can result from three main sources: 
synthetic compounds, natural products, and existing drugs.
Parkinson’s disease (PD) is a common neurodegenerative disease affecting 
1–3% of the adult population over 50 years of age worldwide. It is initially 
characterized by the death of dopaminergic neurons in the substantia nigra 
pars compact and later by the widespread loss of nondopaminergic neurons, 
including those in the cortex (Goedert et al., 2013). Inflammation is the main 
underlying cause in most, if not all, neurodegenerative diseases, playing a protec-
tive role in their initial acute phases, but a pernicious one in their later chronic 
phases. Increasing evidence has disclosed that microglia-mediated neuroin-
flammation is crucial for PD progression (Hirsch and Hunot, 2009). Another 
neuropathological hallmark of PD is the presence of Lewy bodies, which are 
primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In 
recent years, important studies on the role of α-Syn in PD have been conducted. 
The α-Syn aggregation in the central nervous system is a pathological process of 
fundamental importance in the development and progression of PD. Aggregates 
of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing 
neurodegeneration either by directly damaging neurons or by activating mi-
croglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch 
and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and 
release process of endogenous α-Syn occurs, triggering microglial activation and 
leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn 
aggregates generate a vicious circle of neuroinflammation and neuronal death in 
PD. The interaction between these two players, α-Syn aggregates and microglial 
cells, is thus believed to be strongly implicated in the inflammatory process that 
accompanies PD progression. However, the molecular mechanisms that underlie 
α-Syn-induced microglia activation are not well understood. 
The α-Syn aggregates act as agonists of some membrane receptors, such as 
Toll-like receptors (TLRs) and PX27, on microglial cells (Dos-Santos-Pereira et 
al., 2018), representing an interesting physiological substance to mimic the neu-
roinflammatory response in vitro and in vivo in a PD context. These aggregates 
are an alternative to the chemical substances commonly used to model PD, such 
as rotenone, paraquat, or 1-methyl-4-phenyl pyridinium. Therefore, therapeutic 
strategies are actively pursued to decrease, or better yet, prevent α-Syn-induced 
microglial cell activation and thus neuroinflammation in PD (Sanchez-Guajardo 
et al., 2015).
Rifampicin (Rif) as a candidate for drug repurposing in PD: The complex 
technology used in drug finding, the long-term assessment procedures, the 
difficulties in blood-brain barrier permeability, among other factors, make the 
process of drug discovery for treating neurodegenerative diseases unsuccessful. 
Repurposing drugs is currently an expeditious approach to detect drug candi-
dates for PD. In this sense, great expectations have been generated regarding 
the role of some antibiotics as neuroprotective agents. Experimental evidence 
currently shows that many features of antibiotics, including anti-inflammatory, 
anti-aggregating, and antioxidant properties, can be beneficial to the treatment 
of neurological disorders (Socias et al., 2018). Rif is a macrocyclic bactericidal 
antibiotic, widely used in the treatment of infectious diseases, especially against 
those caused by Mycobacterium, such as tuberculosis and leprosy. After oral 
administration, this antibiotic is rapidly absorbed and distributed throughout 
all tissues and humors, as it has the ability to pass into the cerebrospinal fluid in 
significant amounts and act against infectious agents in both cellular and extra-
cellular locations.
   Besides its well-known antibacterial activity, Rif was the first antibiotic reported 
to play a significant protective role in neurodegenerative diseases. It was shown 
that leprosy patients under chronic treatment with Rif displayed a significantly 
decreased prevalence of dementia (McGeer et al., 1992). Since that paper was 
published, a growing number of studies have also revealed that Rif provides ther-
apeutic benefits in chronic neurodegenerative disorders. However, the structural 
or molecular characteristic responsible for conferring this therapeutic effect re-
mains unknown. In this scenario, we have focused our attention on the structural 
and chemical features of Rif to elucidate a possible structure-neuroprotective 
function relationship. Indeed, when Rif is immersed in an aqueous solution, the 
resulting oxidation processes lead to the formation of different species, influ-
enced mainly by pH (Li et al., 2004). The most abundant and probably the most 
interesting of these species is Rif quinone (RifQ), which differs from Rif in that 
a central group corresponding to a dihydro quinone, such as p-benzoquinone, is 
found in a higher oxidation state. 
The anti-neuroinflammatory capacity of RifQ: We have recently reported the 
results of a study on Rif and RifQ (Acuña et al., 2019). The main goals of our 
study were to describe some of the mechanisms through which α-Syn fibrils 
induce in vitro microglial inflammation leading to neuron death and to evaluate 
the ability of RifQ to mitigate this process in comparison with Rif. We initially 
observed that the fibril state was the most inflammogenic α-Syn species in pri-
mary murine microglial cultures. Then, we described the cell receptors through 
which α-Syn fibrils interact and the signaling pathway leading to the production 
of pro-inflammatory substances. We noted that the crucial metabolites released 
as a result of this microglial response induce the death of primary murine corti-
cal neurons. Finally, we demonstrated that a microglial pretreatment with RifQ is 
able to significantly reduce the inflammogenic response and the consequent neu-
ronal damage. Our results suggest that after the interaction of α-Syn fibrils with 
TLR2 and P2X7 membrane receptors, the PI3K/AKT pathway is activated. As a 
consequence, we detected tumor necrosis factor-alpha and interleukin-6 release 
as well as reactive oxygen species generation. The pretreatment of microglial cul-
tures with RifQ prevents the production of α-Syn fibril-induced pro-inflamma-
tory factors, thus increasing the neuron survival. Notably, the anti-inflammatory 
properties of the RifQ pretreatment were not exclusive to α-Syn fibril induction, 
since we also observed this anti-inflammatory ability when microglia were chal-
lenged with TLR2 or P2X7 agonists, Pam3CSK4 and bz-ATP, respectively. Our 
results confirm that inflammatory microglia release neurotoxic metabolites and 
that a compound like RifQ could prevent the neuronal death by a suppressive 
effect on microglial-inflammation (Figure 1A). In a previous study, we had eval-
uated the pro-inflammatory potential of amyloid fibrils of α-Syn by using glu-
tamate as an inflammatory marker (Dos-Santos-Pereira et al., 2018). We found 
that α-Syn fibrils had a strong stimulatory effect on glutamate release through a 
sequence of signaling events and that this stimulatory effect was suppressed by 
the dopamine neurotransmitter. Altogether, these results show the inflammatory 
mechanism involved in PD and the way in which some molecules may be useful 
in preventing or slowing the progression of the neurodegenerative diseases, such 
as PD, which exhibit altered glial function.
We suggest that RifQ could be a candidate molecule for the treatment of PD 
either by interfering with inflammatory processes or by preventing the accumu-
lation of pro-inflammatory microglial cell activators, like α-Syn aggregates. In 
addition, our results suggest that RifQ could be behind some of the properties 
attributed to Rif and that the p-benzoquinone group of the molecule could be 
specifically associated with some chemical and biological effects, as previously 
observed by Konrad and Stenberg (1988). Regarding aggregation protein inhi-
Figure 1  ????????
(A) A model showing how RifQ affects the inflammatory reaction 
of microglial cells. α-Syn fibrils bind microglial TLR2 and P2X7 
receptors, which results in phosphorylation of AKT by PI3K. This 
induces reactive oxygen species production by activation of the 
reduced NOX and release of cytokines. These substances are po-
tentially harmful for neuronal cells. RifQ has a suppressive effect 
on inflammatory mediators release due, in part, to inhibition of 
PI3K dependent signaling events. The inhibitory effects that RifQ 
exerts on α-Syn fibrils activated microglia could provide indirect 
protection to neuronal cells. AKT: NOX: nicotinamide adenine 
dinucleotide phosphate oxidase enzyme; PI3K: RifQ: rifampicin 
quinone; α-Syn: α-synuclein; TLR2: Toll-like receptor 2. (B) Bi-
ological assays to determine the potential of rifampicin quinone 
in therapies for Parkinson’s disease. The research path towards 
efficient use of rifampicin quinone involves a multimodal analysis. 
Such analysis should comprise immune modulation, anti-aggre-
gative, antioxidant, and antimicrobial features, followed by a set 
of tests including in vivo toxicity, drug interactions, and effects 
on microbiota-gut-brain axis signaling to identify whether there 
could be positive effects against Parkinson’s disease.
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bition, it was previously reported that Rif plays an anti-aggregating role not only 
in the human α-Syn, stabilizing its monomeric form, but also in other proteins 
involved in neurodegenerative diseases, like amyloid-β and tau, thus indicating 
its broad spectrum (Li et al., 2004; Socias et al., 2018). It was also shown that Rif 
and p-benzoquinone served as effective inhibitors against in vitro amyloid fibril-
logenesis of lysozyme, suggesting that these molecules may be used in a rational 
design of effective therapeutics for amyloidogenic diseases (Lieu et al., 2007). 
In this sense, RifQ is like a combination of Rif and p-benzoquinone in the same 
molecule. However, as opposed to Rif, not many trials have been conducted with 
RifQ over time. The only study using oxidized species of Rif in processes related 
to neurodegenerative diseases was conducted by Li et al. (2004), employing an 
aged preparation of Rif, where a combination of rusty species was present. This 
formulation was reported to have more potent anti-aggregating effects than Rif (Li 
et al., 2004). Furthermore, other studies have also reported that oxidized deriv-
atives of certain molecules would be more effective in inhibiting protein aggre-
gation. Quinone formation has previously been reported as the potential mech-
anism of inhibition of α-Syn aggregation by the phenolic compound baicalein 
(Zhu et al., 2004). Also, oxidized derivatives of benzoic acid are more effective in 
inhibiting α-Synfibrillation and could be attributed to the combined properties 
of their three -OH groups and quinone-forming structures (Ardah et al., 2014). 
The presence of such oxidized products probably increases the stability of the 
compound binding to the α-Syn fibrils, accounting for the increased inhibitory 
potency of these compounds in a protein-aggregation process.
As regards the background on inflammation processes, several studies have 
also reported the positive effects of Rif, supporting its potential clinical applica-
tions to prevent the neuroinflammation (Socias et al., 2018). In addition, experi-
ments carried out with quinone molecules have been reported to have effects on 
both the prevention and stimulation of inflammation. However, these effects are 
not fully understood yet. It is necessary to determine whether the presence of the 
structural motifs mentioned above, which have anti-aggregative implications, 
is also important in drugs that can be used as immunomodulators against neu-
roinflammatory processes. In this regard, Rif was tested as a potential immuno-
suppressive agent in rats, and the immunosuppressive effect ascribed to Rif was 
found to be, in fact, due to RifQ (Konrad and Stenberg, 1988).
Reflections and perspectives: Despite the great number of reports on the bene-
ficial effects of Rif in PD pathology, analyses using pure RifQ have not been per-
formed to date. Our data are promising adequately to justify further experiments 
to confirm the potential of RifQ as an antiparkinsonian drug. We suggest that 
RifQ should be carefully examined to know this molecule in-depth before this 
antibiotic is administered in chronic therapy.
As we previously noticed, a noxious circle in which protein aggregation in-
duces neuroinflammation and neuronal death and vice versa is playing in PD. 
Keeping this in mind, therapeutic strategies should be focused in blocking all the 
possible factors leading to neurodegeneration. In this line, since α-Syn aggrega-
tion is one of the most important events of that detrimental circle, RifQ should 
be block the amyloid pathway to be adequate for using in the early stage of PD. 
Unfortunately, the difficulty for early diagnosis may interfere with the success of 
therapy and the pertinent starting points for treatment may have passed. Never-
theless, RifQ could be also beneficial at later stages as long as it could mitigate the 
injurious microglia reaction induced by α-Syn aggregates (particularly oxidative 
stress and inflammation) and diminish the neuronal death. In vivo anti-oxidative, 
anti-proliferative and anti-inflammatory properties may contribute to combat 
degeneration and neuronal death. In this scenario, it is now crucial to investigate 
these parameters in animal models when the process of neurodegeneration is 
already engaged.
Although RifQ could represent a potential option to treat neuroinflammation, 
as explained above, its anti-bacterial activity might also be a potential problem 
for long-term therapy. An alternative to avoid this inconvenience is to test wheth-
er RifQ could exert neuroprotective action at sub-antibiotic doses in vivo without 
disturbing microbiome communities. Another option would involve developing 
RifQ chemical analogs without anti-bacterial action but retaining their neuro-
protective properties, or with the same anti-bacterial action but having an en-
hanced neuroprotective effect for long-term administration at lower doses. An-
other interesting perspective in understanding the antibiotic features of RifQ is 
the antimicrobial activity against bacteria from microbiota involved in the brain-
gut axis, particularly the bacterial strains that have been found to play a leading 
role in PD. A recently described pathway for gut bacterial levodopa metabolism 
was found to reduce its bioavailability and to probably decrease its efficacy in PD 
patients (Maini Rekdal et al., 2019). This pathway involves the decarboxylation 
of levodopa to dopamine by Enterococcus faecalis and, subsequently, dehydrox-
ylation of dopamine by Eggerthella lenta to form m-Tyramine (Maini Rekdal et 
al., 2019). Does RifQ have antimicrobial activity against these strains? Can RifQ 
block or diminish the activity of the microbial enzymes involved in L-dopa me-
tabolism in the human gut at sub-antibiotic concentrations? Deciphering these 
connections may be an important research avenue to know drug interactions to 
eventually improve levodopa efficacy and the success in the treatment of PD.
Against this background, it remains to be determined whether any effects of 
Rif would be mainly caused by the oxidized species RifQ. Therefore, multiple 
comparisons between RifQ and Rif would help elucidate the structure-function 
relationship of these molecules. RifQ, like any other antibiotic, may exert selec-
tive pressure against microorganisms normally found in the human microbiota, 
and therefore, affecting the physiologic processes that they are involved by per-
turbing the symbiotic interaction microbia/human. For that, in vitro differences 
between RifQ and Rif of their antimicrobial properties including spectral action, 
resistant bacteria selection and minimal inhibitory concentrations against human 
gut bacteria could also be relevant points to be compared in order to elucidate 
the linkage between chemical structure and biological functions. By determining 
these relationships, we would expand the knowledge required to establish the 
chemical components that should be present to repurpose or design drugs to 
combat neurodegenerative diseases. An overview of experiments and future per-
spectives is summarized in Figure 1B.
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